Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | LDHB | P07195 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28755053 | 0.81 | SCN9A (0.36) | SCN9AMAPTKMT2AMAPK14LDHA | |
| SCHEMBL4045195 | 0.75 | ALDH1A1 (0.38) | MAPTALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL6490290 | 0.74 | KMT2A (0.45) | MAPTALDH1A1KMT2ATSHRDPP4 | |
| SCHEMBL1554049 | 0.74 | ALDH1A1 (0.42) | MAPTALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL13905760 | 0.72 | TSHR (0.40) | MAPTALDH1A1SMN1; SMN2KMT2ARXFP1 | |
| SCHEMBL24895604 | 0.71 | ALDH1A1 (0.37) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL17601005 | 0.70 | IDH1 (0.44) | LMNAGAASMN1; SMN2KMT2ATSHR | |
| SCHEMBL3525337 | 0.69 | ALDH1A1 (0.40) | SCN9AMAPTALDH1A1LMNAGAA | |
| SCHEMBL6488894 | 0.69 | MAPT (0.39) | SCN9AMAPTALDH1A1LMNAGAA | |
| SCHEMBL1874244 | 0.69 | MAPK9 (0.53) | MAPTALDH1A1LMNAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032566-A4 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD (CA) | 2009-07-08 | — | — | EP | claimed |
| EP-2032566-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-03-11 | — | — | EP | claimed |
| WO-2007143823-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-12-21 | — | — | WO | claimed |
| EP-2032566-A4 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD (CA) | 2009-07-08 | — | — | EP | disclosed |
| EP-1539761-B1 | 6,7-DIHYDRO-5H-PYRAZOLO¬1,2-A PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | PROCTER & GAMBLE (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2032566-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-7368455-B2 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368455-B2 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368455-B2 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7326714-B2 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326714-B2 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-6677337-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | PROCTER & GAMBLE COMPANY, THE | 2003-12-04 | — | — | US | disclosed |
| WO-2003080184-A1 | 1,2-DIHYDROPYRAZOL-3-ONES AS CYTOKINE MEDIATORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
| US-20030134867-A1 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2003-07-17 | — | — | US | disclosed |
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2003-06-05 | — | — | US | disclosed |
| US-20030096814-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-05-22 | — | — | US | disclosed |
| WO-2003024970-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024971-A1 | 6,7-DIHYDRO-5H-PYRAZOLO[1,2-A]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002094266-A1 | ISOXAZOLONE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | IL1B, IL1A, TNF | SCN9A 1733/4885MAPT 4424/4885ALDH1A1 221/4885 |
| US-20030096814-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | TNF, IL5, GPR35 | SCN9A 4128/4885MAPT 1010/4885ALDH1A1 2342/4885 |
| US-20030134867-A1 | 6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines | IL1B, IL6, IL1A | SCN9A 353/4885MAPT 4685/4885ALDH1A1 795/4885 |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | IL1B, IL1A, IL1R1 | SCN9A 2871/4885MAPT 4523/4885ALDH1A1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.